Pro-Dex, Inc. PDEX R2K

Healthcare · Medical Instruments & Supplies · United States

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Market & Price

Market Cap

$206.79M

Current Price

$64.77

High / Low (52W)

$67.50 / $23.91

Beta

-0.11

Valuation

Stock P/E

17.84

Industry PE

23.65

Forward P/E

31.44

PEG Ratio

Book Value

$14.14

Price to Book

4.58

P/S

2.77

EV/EBITDA

17.84

Dividend Yield

Profitability & Returns

ROCE

27.68%

ROE

29.83%

ROA

9.70%

Profit Margin

16.08%

Op Margin

15.51%

EPS (Latest Qtr)

$1.20

EPS (TTM)

$3.63

Balance Sheet & Liquidity

Debt/Equity

0.45

Quick Ratio

2.10

Current Ratio

3.67

Debt

$20.17M

Total Assets

$61.19M

Current Assets

$47.30M

Working Capital

$32.67M

Ownership

Promoter Holding

36.49%

Chg in Prom Hold

FII / Inst Holding

32.30%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$215.99M

Total Revenue (TTM)

$74.64M

EBITDA

$12.11M

Free Cash Flow

$5.40M

Operating Cash Flow

$7.34M

Shares Outstanding

3.19M

Gross Margin

27.78%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

16.57%

Profit 5Y

25.23%

Revenue (YoY)

14.60%

Earnings (YoY)

22.40%

PROS

Strong return on equity of 29.8%.
Healthy ROCE of 27.7%.
Compounding revenue at 16.6% over 5 years.
Profit CAGR of 25.2% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PDEX Pro-Dex, Inc. R2K	64.77	17.84	$206.79M	-	27.68%	29.83%	16.57%	25.23%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2014	Sep 2014	Dec 2014	Mar 2015	Sep 2015	Dec 2015	Mar 2016	Sep 2016	Dec 2016	Mar 2017	Sep 2017	Dec 2017	Mar 2018	Sep 2018	Dec 2018	Mar 2019	Sep 2019	Dec 2019	Mar 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Sep 2023	Dec 2023	Mar 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	6.62M	5.16M	5.56M	5.49M	6.92M	6.40M	6.85M	7.24M	7.96M	8.51M	8.59M	8.27M	11.74M	-	9.99M	10.17M	9.27M	-	11.09M	11.28M	13.08M	11.94M	12.59M	14.29M	14.89M	-	17.41M	17.49M	18.53M	18.66M	19.95M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.62M	14.00M	13.16M	12.92M	13.82M
Gross Profit	540.00K	828.00K	696.00K	1.04M	1.06M	1.43M	1.31M	1.42M	1.31M	2.46M	1.86M	1.72M	1.98M	2.73M	2.25M	2.26M	2.78M	2.86M	3.21M	3.48M	2.60M	4.38M	-	3.43M	3.40M	2.86M	-	2.96M	2.62M	3.81M	3.66M	2.80M	4.00M	5.15M	-	5.80M	3.49M	5.37M	5.74M	6.13M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.16M	2.15M	2.26M	2.48M	3.04M
Operating Income	-438.00K	-189.00K	-393.00K	-390.00K	-119.00K	486.00K	176.00K	294.00K	269.00K	1.35M	874.00K	350.00K	632.00K	1.73M	1.19M	897.00K	1.49M	1.67M	1.70M	1.55M	521.00K	1.86M	-	1.32M	1.60M	1.02M	-	950.00K	1.14M	2.06M	1.83M	777.00K	2.21M	3.01M	-	3.64M	1.34M	3.11M	3.26M	3.09M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.11M	2.14M	6.73M	3.38M	5.90M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	246.00K	227.00K	200.00K	141.00K	201.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.55M	1.60M	6.22M	2.93M	5.34M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.28M	402.00K	1.54M	741.00K	1.40M
Net Income	-385.00K	-170.00K	-192.00K	-76.00K	-125.00K	391.00K	368.00K	286.00K	3.19M	888.00K	628.00K	345.00K	480.00K	1.35M	1.18M	732.00K	1.10M	1.25M	1.21M	1.11M	1.79M	2.16M	1.11M	1.08M	1.08M	574.00K	1.84M	1.20M	2.75M	1.62M	-615.00K	500.00K	655.00K	2.47M	-	3.27M	1.20M	4.68M	2.19M	3.94M
Diluted EPS	-	-0.04	-0.05	-0.02	-0.03	0.09	0.09	0.07	0.78	0.22	0.15	0.08	0.11	0.31	0.28	0.17	0.27	0.31	0.30	0.28	0.45	0.54	0.28	0.29	0.29	0.15	0.49	0.33	0.75	0.45	-0.17	0.14	0.19	0.75	-	0.98	0.36	1.40	0.66	1.20
R&D Expense	381.00K	384.00K	444.00K	480.00K	429.00K	264.00K	301.00K	304.00K	278.00K	257.00K	407.00K	478.00K	560.00K	408.00K	326.00K	603.00K	484.00K	397.00K	620.00K	1.09M	989.00K	1.10M	-	980.00K	615.00K	658.00K	-	929.00K	467.00K	713.00K	805.00K	788.00K	760.00K	843.00K	942.00K	947.00K	-	768.00K	734.00K	827.00K

Profit & Loss (Annual)

Figures in USD.

Metric	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Revenue	-	6.71M	722.00K	-	13.38M	20.16M	21.94M	22.46M	27.17M	34.83M	-	42.04M	46.09M	53.84M	66.59M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	28.91M	33.34M	39.29M	47.08M
Gross Profit	10.14M	5.42M	3.72M	2.97M	3.70M	4.92M	7.19M	7.94M	9.78M	13.14M	-	13.13M	12.75M	14.55M	19.51M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	7.97M	6.99M	7.38M	8.82M
Operating Income	3.48M	-1.36M	-1.90M	-814.00K	-902.00K	807.00K	2.74M	2.39M	5.00M	7.07M	-	5.16M	5.76M	7.17M	10.69M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	6.88M	10.82M	4.35M	14.13M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	464.00K	533.00K	558.00K	829.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	5.69M	9.43M	2.63M	12.06M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	1.12M	2.35M	507.00K	3.08M
Net Income	2.64M	-876.00K	-1.78M	-488.00K	-365.00K	822.00K	5.08M	1.62M	4.15M	6.11M	-	4.57M	7.07M	2.13M	8.98M
Diluted EPS	0.80	-0.27	-	-	-0.09	0.20	1.25	0.37	0.97	1.50	-	1.02	1.98	0.60	2.67
R&D Expense	1.89M	2.07M	1.79M	1.48M	1.67M	1.20M	1.23M	1.89M	1.88M	2.31M	4.38M	2.98M	2.80M	3.19M	3.64M

Compounded Sales Growth

5 Years:	16.57%
1 Year:	14.60%

Compounded Profit Growth

5 Years:	25.23%
1 Year:	22.40%

Stock Price Performance

1 Year:	+61.72%
6 Months:	+77.89%
3 Months:	+46.17%
1 Month:	+29.96%

Balance Sheet (Annual)

Figures in USD.

Metric	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jul 2019	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Jun 2024	Jun 2025
Total Assets	-	15.56M	12.82M	10.60M	11.71M	12.52M	11.15M	16.35M	19.92M	25.52M	-	31.13M	31.45M	39.06M	43.04M	-	42.93M	43.33M	45.22M	49.09M	49.85M	51.88M	51.69M	51.82M	52.48M	61.19M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.17M	-	-	-	30.98M	36.61M	47.30M
Cash & Equivalents	3.79M	4.69M	4.11M	1.68M	3.19M	697.00K	2.29M	4.21M	5.19M	7.74M	-	6.42M	-	-	-	-	-	-	-	849.00K	-	-	-	2.94M	2.63M	419.00K
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.68M	-	-	-	16.17M	15.27M	22.21M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.38M	-	-	-	9.95M	13.89M	16.43M
Total Liabilities	-	5.24M	3.27M	2.66M	2.49M	4.04M	2.27M	2.64M	2.64M	8.51M	3.30M	12.06M	-	-	-	-	-	-	-	23.66M	-	23.64M	21.79M	20.23M	21.61M	24.56M
Current Liabilities	-	4.02M	2.88M	2.31M	2.13M	3.69M	2.16M	2.58M	2.42M	4.27M	-	5.23M	-	-	-	-	-	-	-	11.35M	-	-	-	9.68M	12.89M	14.63M
Long Term Debt	-	1.22M	393.00K	-	-	-	-	-	-	4.60M	-	3.98M	-	-	-	-	-	-	-	10.25M	-	-	-	8.91M	7.54M	9.25M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.97M	-	-	-	14.79M	13.55M	16.58M
Total Equity	7.62M	10.32M	9.55M	7.94M	9.22M	8.48M	8.88M	13.71M	17.28M	17.01M	-	19.06M	-	-	-	-	-	-	-	25.43M	-	-	-	31.59M	30.87M	36.63M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.60M	-	-	-	3.55M	3.36M	3.26M

Cash Flows (Annual)

Figures in USD.

Metric	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Operating Cash Flow	2.90M	45.00K	-1.27M	-329.00K	-	466.00K	3.23M	3.10M	3.33M	4.95M	-	-847.00K	5.46M	6.22M	-1.68M
Investing Cash Flow	-265.00K	-259.00K	-452.00K	323.00K	-	1.59M	-1.03M	-4.12M	-1.22M	-2.29M	-	-1.24M	-885.00K	-2.23M	-238.00K
Financing Cash Flow	-1.74M	-363.00K	-709.00K	1.51M	-	-457.00K	-298.00K	2.00M	450.00K	-3.98M	-	-790.00K	-2.49M	-4.30M	-292.00K
Capital Expenditure	-	-	-	-	-	-	-	-	-1.39M	-519.00K	-	-1.67M	-974.00K	-983.00K	-1.25M
Free Cash Flow	-	-	-	-	-	-	-	-	1.94M	4.43M	-	-2.52M	4.49M	5.24M	-2.93M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-2.87M	2.09M	-305.00K	-2.21M
Share Buybacks	-	6.00K	-	-	154.00K	454.00K	312.00K	220.00K	3.98M	3.39M	5.54M	1.61M	1.55M	3.50M	3.50M

Ratios (Annual)

Figures in %.

Metric	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Gross Margin %	-	80.7%	514.7%	-	27.7%	24.4%	32.7%	35.4%	36.0%	37.7%	-	31.2%	27.7%	27.0%	29.3%
Operating Margin %	-	-20.3%	-262.5%	-	-6.7%	4.0%	12.5%	10.6%	18.4%	20.3%	-	12.3%	12.5%	13.3%	16.1%
Net Margin %	-	-13.1%	-247.1%	-	-2.7%	4.1%	23.2%	7.2%	15.3%	17.5%	-	10.9%	15.3%	4.0%	13.5%
ROE %	25.6%	-9.2%	-22.5%	-5.3%	-4.3%	9.3%	37.1%	9.4%	24.4%	32.1%	-	18.0%	22.4%	6.9%	24.5%
ROCE %	30.1%	-13.7%	-22.9%	-8.5%	-10.2%	9.0%	19.9%	13.7%	23.5%	27.3%	-	13.7%	13.7%	18.1%	23.0%

Shareholding Pattern

Insiders

36.49%

Institutions

32.30%

Public Float

50.86%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	4.78%	152.51K	$9.88M
2	Vanguard Capital Management LLC	3.49%	111.33K	$7.21M
3	Punch & Associates Investment Management, Inc.	1.93%	61.73K	$4.00M
4	Dimensional Fund Advisors LP	1.78%	56.94K	$3.69M
5	Geode Capital Management, LLC	1.51%	48.35K	$3.13M
6	Northern Trust Corporation	1.46%	46.69K	$3.02M
7	State Street Corporation	1.04%	33.11K	$2.14M
8	JPMORGAN CHASE & CO	1.00%	32.04K	$2.07M
9	Quadrature Capital Ltd	0.47%	14.99K	$970.64K
10	Morgan Stanley	0.45%	14.21K	$920.58K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PDEX

No recent headlines available.

PDEX · Healthcare

Pro-Dex, Inc.

About

Key Facts

Sector	Healthcare
Industry	Medical Instruments & Supplies
Headquarters	United States
Employees	179
Website	https://www.pro-dex.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Pro-Dex, Inc. PDEX R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More